Holen Sie sich die Stockscreener-App
4.48
0.44%
-0.02
Schlusskurs vom Vortag:
$4.50
Offen:
$4.55
24-Stunden-Volumen:
8,046
Relative Volume:
0.16
Marktkapitalisierung:
$86.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.17M
KGV:
-1.9792
EPS:
-2.2635
Netto-Cashflow:
$-47.63M
1W Leistung:
-1.10%
1M Leistung:
+5.66%
6M Leistung:
+17.89%
1J Leistung:
+65.31%
1-Tages-Spanne:
$4.4707
$4.59
1-Wochen-Bereich:
$4.365
$4.61
52-Wochen-Spanne:
$2.44
$5.12
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.53 | 85.87M | 0 | -34.17M | -47.63M | -2.2635 |
VRTX
Vertex Pharmaceuticals Inc
|
428.58 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
719.58 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.32 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.35 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.54 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 - The Manila Times
Aurum holds 5,001,561 shares in Polypid Ltd. (PYPD) with exercisable warrants - Stock Titan
AIGH Capital Management LLC Has $5.83 Million Stock Position in PolyPid Ltd. $PYPD - MarketBeat
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting - BioSpace
PolyPid to present wound infection data at surgery conference - Investing.com
PolyPid to present wound infection data at surgery conference By Investing.com - Investing.com Canada
PYPD Price Today: PolyPid Ltd. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Increases By 166.1% - MarketBeat
PYPD (PolyPid Ltd. Ordinary Shares) reports wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Tây Ninh
PolyPid (PYPD) Stock Outlook | Q4 2025: Earnings UnderperformHigh Growth - Cổng thông tin điện tử tỉnh Lào Cai
PolyPid Ltd stock (US70450B1035): Is its drug-delivery tech strong enough to unlock biotech upside? - AD HOC NEWS
PolyPid Ltd stock (US70450B1035): Is its drug delivery tech strong enough to unlock surgical market - AD HOC NEWS
Nir Dror Darwish Net Worth (2026) - GuruFocus
Itzhak Krinsky Net Worth (2026) - GuruFocus
PolyPid (PYPD) Stock Recovery Underway (-1.27%) 2026-04-16Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Yechezkel Barenholz Net Worth (2026) - GuruFocus
Dikla Czaczkes Akselbrad Net Worth (2026) - GuruFocus
Jonathan Missulawin Net Worth (2026) - GuruFocus
Yitzchak Shlomo Jacobovitz Net Worth (2026) - GuruFocus
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference - Sahm
PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026 - RTTNews
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global By Investing.com - Investing.com Australia
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 - markets.businessinsider.com
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global - Investing.com
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating - GlobeNewswire
Short Covering: How much upside does PolyPid Ltd have2026 Key Lessons & Weekly High Return Stock Forecasts - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - MarketBeat
PYPD Options Volatility — NASDAQ:PYPD - TradingView
PYPD Options Chain — NASDAQ:PYPD - TradingView
PolyPid (NASDAQ:PYPD) Stock Price Up 3.3%Still a Buy? - MarketBeat
Market Rankings: Is PolyPid Ltd likely to announce a buybackPortfolio Gains Summary & Smart Swing Trading Techniques - baoquankhu1.vn
PYPD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Gainers: Does PolyPid Ltd have high return on assets2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
PolyPid (PYPD) director submits initial Form 3 ownership - Stock Titan
PolyPid (PYPD) director details vested and future stock options - Stock Titan
Can PolyPid (PYPD) Stock Beat Estimates | Price at $4.24, Down 3.42%Expert Verified Trades - Newser
Total equity of PolyPid Ltd. – FWB:2PV - TradingView
Total debt of PolyPid Ltd. – FWB:2PV - TradingView
PolyPid Ltd. Balance Sheet – FWB:2PV - TradingView
Cash per share of PolyPid Ltd. – FWB:2PV - TradingView — Track All Markets
PolyPid Ltd. Stock (2PV)Quote Deutsche Boerse AG - marketscreener.com
PolyPid Ltd.: Target Price Consensus and Analysts Recommendations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Revenue and Earnings Analysts Forecasts Revisions | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Financial Data Forecasts Estimates and Expectations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Shareholders Board Members Managers and Company Profile | IL0011326795 - marketscreener.com
PolyPid Ltd.: Fundamental Analysis and Financial Ratings | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Performance & Quotes, 2PV Stock Price on Deutsche Boerse AG Exchange - marketscreener.com
Taxes of PolyPid Ltd. – FWB:2PV - TradingView
2PV: Static price chart | PolyPid Ltd. | IL0011326795 - marketscreener.com
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):